HTG Molecular Diagnostics Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

John Lubniewski

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	6.8yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	8.8yrs
Yönetim Kurulu ortalama görev süresi	5.8yrs

Son yönetim güncellemeleri

Recent updates

These Analysts Think HTG Molecular Diagnostics, Inc.'s (NASDAQ:HTGM) Sales Are Under Threat

Mar 26

What Type Of Returns Would HTG Molecular Diagnostics'(NASDAQ:HTGM) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Jan 20

HTG shares surge after upbeat 2020 revenue forecast

Jan 05

HTG Molecular Diagnostics announced 1:15 reverse stock split

Nov 23

HTG Molecular Diagnostics (HTGM) Investor Presentation - Slideshow

Nov 18

CEO Tazminat Analizi

John Lubniewski'un ücretlendirmesi HTG Molecular Diagnostics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2023	n/a	n/a	-US$20m
Dec 31 2022	US$914k	US$538k	-US$22m
Sep 30 2022	n/a	n/a	-US$22m
Jun 30 2022	n/a	n/a	-US$22m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$737k	US$460k	-US$17m
Sep 30 2021	n/a	n/a	-US$16m
Jun 30 2021	n/a	n/a	-US$17m
Mar 31 2021	n/a	n/a	-US$20m
Dec 31 2020	US$1m	US$416k	-US$21m
Sep 30 2020	n/a	n/a	-US$21m
Jun 30 2020	n/a	n/a	-US$20m
Mar 31 2020	n/a	n/a	-US$19m
Dec 31 2019	US$1m	US$384k	-US$19m
Sep 30 2019	n/a	n/a	-US$17m
Jun 30 2019	n/a	n/a	-US$17m
Mar 31 2019	n/a	n/a	-US$16m
Dec 31 2018	US$1m	US$327k	-US$16m

Tazminat ve Piyasa: John şirketinin toplam tazminatının US pazarındaki benzer büyüklükteki şirketlerle karşılaştırıldığında makul olup olmadığını tespit etmek için yeterli veri yok.

Tazminat ve Kazançlar: John şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

John Lubniewski (60 yo)

6.8yrs

Görev süresi

US$913,891

Tazminat

Mr. John L. Lubniewski serves as President of HTG Molecular Diagnostics, Inc. since April 16, 2018 and also serves as its Chief Executive Officer since April 2019. Mr. Lubniewski served as Chief Operating...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
John Lubniewski	President	6.8yrs	US$913.89k	Veri yok
Shaun McMeans	Senior VP	13yrs	US$580.32k	Veri yok
Laura Godlewski	Senior Vice President of Finance & Administration	3.1yrs	Veri yok	Veri yok
Debra Gordon	Senior VP & Chief Legal Counsel	13.7yrs	US$296.70k	Veri yok
Patrick Roche	Senior Vice President of Research & Development	10.8yrs	US$507.38k	Veri yok
Stephen Barat	Senior Vice President of Therapeutics	3.3yrs	Veri yok	0.019% $ 0.0004
Christina Carruthers	Vice President of Target Strategy & Early Development	no data	Veri yok	Veri yok
Debrah Thompson	Vice President of Scientific Innovation	no data	Veri yok	Veri yok

8.8yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim: HTGM.Q 'un yönetim ekibi deneyimli ve deneyimlidir ( 8.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
John Lubniewski	President	5.8yrs	US$913.89k	Veri yok
Michelle Griffin	Independent Director	6.5yrs	US$54.75k	Veri yok
Lee McCracken	Independent Director	9.3yrs	US$49.41k	Veri yok
Ann Hanham	Independent Chairman of the Board	8.5yrs	US$80.05k	Veri yok
Thomas Dubensky	Independent Director	2.5yrs	US$11.00k	Veri yok
Christopher Kiritsy	Non-Employee Independent Director	3.1yrs	US$53.83k	Veri yok
Davide Ruggero	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Frank Slack	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Robert Spitale	Member of Therapeutics Scientific Advisory Board	3yrs	Veri yok	Veri yok
Amir Horowitz	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Mateusz Koptyra	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Kendall Van Keuren-Jensen	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

5.8yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: HTGM.Q 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.8 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/02/01 03:28
Gün Sonu Hisse Fiyatı	2025/01/08 00:00
Kazançlar	2023/03/31
Yıllık Kazançlar	2022/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

HTG Molecular Diagnostics, Inc. 6 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Mark Massaro	Canaccord Genuity
Kristen Kluska	Cantor Fitzgerald & Co.
Alexander Nowak	Craig-Hallum Capital Group LLC

HTG Molecular Diagnostics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Htg Molecular Diagnostics, Inc. Announces Termination of Employment of Byron T. Lawson as Senior Vice President and Chief Commercial Officer

HTG Molecular Diagnostics, Inc. Announces Board Changes

HTG Molecular Diagnostics, Inc., Annual General Meeting, Aug 17, 2022

HTG Molecular Diagnostics, Inc. Appoints Dr. Robert Spitale to Therapeutics Scientific Advisory Board

HTG Molecular Diagnostics, Inc. Appoints Christopher P. Kiritsy to Serve as Class I Director, Member of Audit Committee

HTG Molecular Diagnostics, Inc. Announces Resignation of Timothy B. Johnson as Executive Chairman and a Member of the Board of Directors

Recent updates

Nasdaq to Delist the Common Stock of HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc.(OTCPK:HTGM.Q) dropped from NASDAQ Composite Index

HTG Molecular Diagnostics, Inc.(NasdaqCM:HTGM) dropped from S&P TMI Index

Htg Molecular Diagnostics, Inc. Announces Termination of Employment of Byron T. Lawson as Senior Vice President and Chief Commercial Officer

HTG Molecular Diagnostics, Inc. Filed for Bankruptcy

HTG Molecular Diagnostics Receives Non-Compliance Notice From Nasdaq

HTG Molecular Diagnostics, Inc. to Highlight the Advantages of its Drug Discovery Engine at the 2023 Biotechnology Innovation Organization

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS misses analyst expectations

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. Provides a Year-End Update on its Drug Discovery Business and Attends LifeSci Partners 2023 Corporate Access Event

HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for Full Year 2022

HTG Molecular Diagnostics, Inc. has completed a Follow-on Equity Offering.

HTG Molecular Diagnostics, Inc. Receives Non-Compliance Notice From Nasdaq

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. announced that it has received $0.0001 million in funding

HTG Molecular Diagnostics Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. Announces Board Changes

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

HTG Molecular Q2 GAAP loss per share widens, revenue down

HTG Molecular Diagnostics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Price target decreased to US$3.25

HTG Molecular Diagnostics amends senior loan facility

HTG Molecular Diagnostics, Inc., Annual General Meeting, Aug 17, 2022

HTG Molecular Diagnostics, Inc. Releases Second Whitepaper for Its Transcriptome-Informed Approach to Drug Discovery

HTG Molecular Diagnostics Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for the Full Year 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

HTG Molecular Diagnostics, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$9.50

HTG Molecular Diagnostics, Inc. Expands Features of Proprietary HTG EdgeSeq Technology

Consensus revenue estimates fall by 16%

Full year 2021 earnings: EPS exceeds analyst expectations

HTG Molecular Diagnostics, Inc. Appoints Dr. Robert Spitale to Therapeutics Scientific Advisory Board

HTG Molecular Diagnostics, Inc. Appoints Christopher P. Kiritsy to Serve as Class I Director, Member of Audit Committee

HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for the Full Year 2021

HTG Molecular Diagnostics, Inc. Completes HTP Product Next-Phase Development Milestone

Is HTG Molecular Diagnostics (NASDAQ:HTGM) Using Debt In A Risky Way?

Third quarter 2021 earnings released: US$0.60 loss per share (vs US$1.12 loss in 3Q 2020)

Is HTG Molecular Diagnostics (NASDAQ:HTGM) Weighed On By Its Debt Load?

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.39 loss per share (vs US$1.30 loss in 2Q 2020)

HTG Molecular Diagnostics, Inc. Announces Commercial Launch and Immediate Availability of its HTG Transcriptome Panel

HTG Molecular Diagnostics, Inc. Announces Completion of Product Design Lock for the HTG Transcriptome Panel

HTG Molecular completes product design lock for planned transcriptome panel

First quarter 2021 earnings released: US$0.64 loss per share (vs US$1.27 loss in 1Q 2020)

Price target decreased to US$9.75

HTG Molecular Diagnostics, Inc. Reports Preliminary Financial Results for the First Quarter Ended March 31, 2021 and Full Year 2021

Full year 2020 earnings released: US$4.51 loss per share (vs US$7.60 loss in FY 2019)

Consensus forecasts updated

Price target decreased to US$11.75

These Analysts Think HTG Molecular Diagnostics, Inc.'s (NASDAQ:HTGM) Sales Are Under Threat

HTG Molecular Diagnostics, Inc. to Report Fiscal Year 2020 Results on Mar 25, 2021

HTG Concludes Feasibility Testing & Releases Second White Paper for its Planned Whole Transcriptome Panel Using HTG EdgeSeq Technology

New 90-day high: US$7.83

New 90-day high: US$7.27

HTG Molecular Diagnostics, Inc. Announces Resignation of Timothy B. Johnson as Executive Chairman and a Member of the Board of Directors

What Type Of Returns Would HTG Molecular Diagnostics'(NASDAQ:HTGM) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Price target lowered to US$9.25

New 90-day high: US$6.10

HTG shares surge after upbeat 2020 revenue forecast

New 90-day high: US$5.61

Analysts update estimates

HTG Molecular Diagnostics announced 1:15 reverse stock split

HTG Molecular Diagnostics (HTGM) Investor Presentation - Slideshow